<!DOCTYPE html><html lang="en" class="__variable_6d343d __variable_49a339"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="/_next/static/media/26d4368bf94c0ec4-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" href="/_next/static/media/36966cca54120369-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" as="image" href="/logo.svg" fetchPriority="high"/><link rel="stylesheet" href="/_next/static/css/5bd3404007bffd2a.css" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" href="/_next/static/chunks/webpack-04cc3a393714a88b.js"/><script src="/_next/static/chunks/fd9d1056-4b87d5bb1aa946b3.js" async=""></script><script src="/_next/static/chunks/23-7a13f39f0e990758.js" async=""></script><script src="/_next/static/chunks/main-app-9c6ab80fd9a4d8e3.js" async=""></script><script src="/_next/static/chunks/231-9e11bdfe3b664aec.js" async=""></script><script src="/_next/static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js" async=""></script><script src="/_next/static/chunks/896-78f6f35c40d7ae60.js" async=""></script><script src="/_next/static/chunks/391-9c591ea098453467.js" async=""></script><script src="/_next/static/chunks/app/layout-6784eb5ba9ddff8d.js" async=""></script><link rel="icon" href="/logo.svg" type="image/svg+xml"/><title>PCK share price, analysis &amp; company profile - Painchek Ltd | ASX Desk</title><meta name="description" content="Latest PCK share price overview, what Painchek Ltd does, bull and bear cases, and AI-powered analysis for ASX investors."/><link rel="canonical" href="https://asxdesk.com/asx/PCK/"/><meta property="og:title" content="PCK share price, analysis &amp; company profile - Painchek Ltd"/><meta property="og:description" content="Latest PCK share price overview, what Painchek Ltd does, bull and bear cases, and AI-powered analysis for ASX investors."/><meta property="og:url" content="https://asxdesk.com/asx/PCK/"/><meta property="og:type" content="article"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:title" content="PCK share price, analysis &amp; company profile - Painchek Ltd"/><meta name="twitter:description" content="Latest PCK share price overview, what Painchek Ltd does, bull and bear cases, and AI-powered analysis for ASX investors."/><meta name="next-size-adjust"/><script src="/_next/static/chunks/polyfills-78c92fac7aa8fdd8.js" noModule=""></script></head><body class="min-h-screen bg-ink-900 text-slate-100"><div class="min-h-screen"><header class="sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur"><div class="mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8"><a class="flex items-center gap-3" href="/"><img alt="ASX Desk" fetchPriority="high" width="140" height="40" decoding="async" data-nimg="1" class="h-10 w-auto" style="color:transparent" src="/logo.svg"/><span class="hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline">Research Terminal</span></a><nav class="hidden items-center gap-6 text-sm text-slate-300 md:flex"><a class="transition hover:text-white" href="/">Home</a><a class="transition hover:text-white" href="/screener/">Screener</a><a class="transition hover:text-white" href="/sectors/">Sectors</a><a class="transition hover:text-white" href="/news/">News</a><a class="transition hover:text-white" href="/ipos/">IPOs</a><a class="transition hover:text-white" href="/compare/">Compare</a><a class="transition hover:text-white" href="/about/">About</a></nav><div class="hidden items-center gap-3 md:flex"><div class="relative"><div class="flex items-center rounded-full border border-white/10 bg-ink-900/70 px-3 py-1.5 focus-within:border-blue-500/60 transition"><svg class="h-4 w-4 shrink-0 text-slate-500" fill="none" stroke="currentColor" viewBox="0 0 24 24" stroke-width="2"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.35-4.35" stroke-linecap="round"></path></svg><input type="text" placeholder="Search tickerâ€¦" class="ml-2 w-36 bg-transparent text-xs text-white placeholder:text-slate-500 focus:outline-none lg:w-44" value=""/></div></div><button class="rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20">Premium Research</button><button class="rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400">Open Account</button></div></div><div class="flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden"><div class="flex-1"><div class="relative"><div class="flex items-center rounded-full border border-white/10 bg-ink-900/70 px-3 py-1.5 focus-within:border-blue-500/60 transition"><svg class="h-4 w-4 shrink-0 text-slate-500" fill="none" stroke="currentColor" viewBox="0 0 24 24" stroke-width="2"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.35-4.35" stroke-linecap="round"></path></svg><input type="text" placeholder="Search tickerâ€¦" class="ml-2 w-36 bg-transparent text-xs text-white placeholder:text-slate-500 focus:outline-none lg:w-44" value=""/></div></div></div><a class="shrink-0 text-xs text-blue-300" href="/screener/">Screener</a></div></header><main class="mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8"><div class="space-y-12"><script type="application/ld+json">{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What does PCK do?","acceptedAnswer":{"@type":"Answer","text":"Painchek Ltd develops and commercialises the PainchekÂ® app, an AI-powered medical device for assessing and documenting pain in individuals unable to verbalise it. It's primarily used in aged care for people with dementia and is expanding into paediatric and acute care settings globally."}},{"@type":"Question","name":"Is PCK a good investment?","acceptedAnswer":{"@type":"Answer","text":"As a micro-cap health tech company, PCK is a speculative investment with significant upside potential if its global expansion and adoption succeed, driven by a unique technology addressing an unmet clinical need. However, it carries risks associated with market penetration, capital requirements, and competition common to early-stage growth companies. Investors should be aware of its potential reliance on future capital raises."}},{"@type":"Question","name":"What drives PCK's share price?","acceptedAnswer":{"@type":"Answer","text":"PCK's share price is primarily driven by announcements of significant contract wins and partnerships, strong growth in subscriber numbers and recurring revenue, successful international expansion milestones (e.g., regulatory approvals), and any positive clinical validation or government support for its technology. Capital raising activities and broader market sentiment towards speculative health tech stocks also play a role."}}]}</script><section class="grid gap-8 lg:grid-cols-[1.6fr_0.8fr]"><div class="space-y-6"><div class="glass-card rounded-2xl p-6"><p class="text-xs uppercase tracking-[0.3em] text-blue-300">Health Care</p><h1 class="mt-3 font-display text-3xl font-semibold">Painchek Ltd<!-- --> (<!-- -->PCK<!-- -->)</h1><p class="mt-4 text-sm text-slate-300">Painchek Ltd (ASX: PCK) is an Australian health technology company that has developed and commercialised the PainchekÂ® app, an AI-powered pain assessment tool. This medical device uses facial recognition and AI to assess and document pain in individuals who cannot reliably verbalise it, primarily targeting people with dementia in aged care and non-verbal children. The company operates in Australia, the UK, New Zealand, and Canada, aiming to address a significant unmet clinical need globally.</p><div class="mt-6 grid gap-4 sm:grid-cols-2"><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-xs text-slate-500">Market Cap</p><p class="mt-2 text-lg font-semibold">A$47M</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-xs text-slate-500">Shares on Issue</p><p class="mt-2 text-lg font-semibold">N/A</p></div></div><div class="mt-6 flex flex-wrap gap-3 text-xs text-slate-400"><a href="" class="rounded-full border border-white/10 px-3 py-1">Company Website</a><span class="rounded-full border border-white/10 px-3 py-1">AI coverage updated hourly</span><span class="rounded-full border border-white/10 px-3 py-1">Data from ASX filings</span></div></div><div class="glass-card rounded-2xl p-6"><h2 class="font-display text-xl font-semibold mb-4">Price Chart</h2><div id="tradingview-widget-PCK" style="height:700px;width:100%"><div class="flex h-full items-center justify-center"><div class="flex items-center gap-3 text-sm text-slate-400"><svg class="h-5 w-5 animate-spin text-blue-400" viewBox="0 0 24 24" fill="none"><circle cx="12" cy="12" r="10" stroke="currentColor" stroke-width="3" class="opacity-25"></circle><path d="M4 12a8 8 0 018-8" stroke="currentColor" stroke-width="3" stroke-linecap="round" class="opacity-75"></path></svg>Loading chartâ€¦</div></div></div></div><section class="space-y-6"><div class="glass-card rounded-2xl p-6"><h2 class="font-display text-xl font-semibold">AI Analysis</h2><div class="mt-4 space-y-4 text-sm text-slate-300"><p>Painchek is in a critical growth phase, actively commercialising its PainchekÂ® software-as-a-service (SaaS) platform, particularly within the Australian aged care sector where it has achieved significant penetration. The company generates recurring revenue through subscriptions, with recent performance focused on increasing user adoption, expanding into new aged care facilities, and securing key partnerships. As a micro-cap, its current financial position often reflects ongoing investment in R&amp;D and market expansion, leading to a focus on user growth and revenue trajectory rather than immediate profitability.</p><p>The growth outlook for Painchek is driven by international expansion, especially in large markets like the UK (e.g., NHS uptake) and potential future entry into the US, along with expanding its application into new segments such as paediatrics and acute care. Upcoming catalysts include securing major contracts with national health systems, achieving significant increases in subscriber numbers, and gaining regulatory approvals in new jurisdictions. The strategic direction centres on establishing Painchek as the global standard for pain assessment in non-verbal populations, leveraging its unique AI technology and a strong clinical evidence base.</p></div></div><div class="grid gap-6 lg:grid-cols-2"><div class="glass-card rounded-2xl p-6"><h3 class="flex items-center gap-2 text-sm font-semibold text-emerald-300">Bull Case</h3><ul class="mt-4 space-y-2 text-sm text-slate-300"><li>â€¢ <!-- -->Accelerated international adoption, particularly securing significant contracts with national health systems (e.g., UK NHS, major US aged care groups), leading to a rapid expansion of recurring revenue.</li><li>â€¢ <!-- -->Successful diversification into new clinical segments beyond aged care, such as paediatrics, acute care, and disability support, significantly expanding the addressable market.</li><li>â€¢ <!-- -->Strong evidence of improved patient outcomes and cost-effectiveness from Painchek&#x27;s use, driving increased clinical acceptance, government reimbursement, and mandatory adoption across healthcare settings.</li></ul></div><div class="glass-card rounded-2xl p-6"><h3 class="flex items-center gap-2 text-sm font-semibold text-red-300">Bear Case</h3><ul class="mt-4 space-y-2 text-sm text-slate-300"><li>â€¢ <!-- -->Slower than anticipated adoption rates due to market resistance, regulatory hurdles, or challenges in securing large-scale national contracts, impacting revenue growth and cash flow.</li><li>â€¢ <!-- -->Persistent reliance on capital raises to fund ongoing operations and growth initiatives, leading to potential share dilution for existing investors, common for speculative small-cap growth companies.</li><li>â€¢ <!-- -->Increased competition from other pain assessment technologies or established clinical practices, or potential technical issues/data security concerns that could undermine trust and market penetration.</li></ul></div></div></section><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">Market Sentiment</h3><div class="mt-4 flex items-center gap-3"><span class="inline-flex items-center gap-1.5 rounded-full border px-3 py-1 text-sm font-semibold bg-yellow-500/10 border-yellow-500/30 text-yellow-400">ðŸŸ¡<!-- --> <!-- -->Mixed</span><span class="text-xs text-slate-500">Score: <!-- -->0.00</span></div><div class="mt-4"><div class="flex justify-between text-[10px] uppercase tracking-widest text-slate-500"><span>Bearish</span><span>Bullish</span></div><div class="relative mt-1 h-2 rounded-full bg-ink-900/60"><div class="absolute left-1/2 top-0 h-full w-px bg-slate-600"></div><div class="absolute top-0 h-full w-2 rounded-full bg-yellow-500" style="left:calc(50% - 4px)"></div></div></div><div class="mt-4 flex gap-4 text-xs"><span class="text-emerald-400">â–² <!-- -->0<!-- --> bullish</span><span class="text-red-400">â–¼ <!-- -->0<!-- --> bearish</span><span class="text-slate-500">10<!-- --> neutral</span></div><p class="mt-1 text-xs text-slate-500">Based on <!-- -->10<!-- --> social post<!-- -->s</p><div class="mt-4 space-y-2"><p class="text-xs uppercase tracking-widest text-slate-500">Recent mentions</p><div class="rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs"><div class="flex items-center gap-2"><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400">hotcopper</span><span class="text-slate-500">2026-02-07</span><span class="text-slate-400">â€”</span></div><p class="mt-1.5 text-slate-300">Introduction to PainChek Ltd</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs"><div class="flex items-center gap-2"><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400">hotcopper</span><span class="text-slate-500">2026-02-08</span><span class="text-slate-400">â€”</span></div><p class="mt-1.5 text-slate-300">Informational post about PAINCHEK LTD</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs"><div class="flex items-center gap-2"><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400">hotcopper</span><span class="text-slate-500">2026-02-08</span><span class="text-slate-400">â€”</span></div><p class="mt-1.5 text-slate-300">Introduction to PainChek Ltd</p></div></div></div><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">Recent Announcements</h3><div class="mt-4 space-y-3 text-sm text-slate-300"><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Quarterly Activities/Appendix 4C Cash Flow Report</p><span class="inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400" title="Price sensitive">ðŸš¨ Price Sensitive</span></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>29 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Quarterly Report</span></div><p class="mt-2 text-xs text-slate-400">PCK, a commitments test entity on ASX, has released its quarterly cash flow report detailing significant capital expenditcur and investment activities for the period.</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">PainChek Business Update</p><span class="inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400" title="Price sensitive">ðŸš¨ Price Sensitive</span></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>29 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Progress Report</span></div><p class="mt-2 text-xs text-slate-400">PainChek (ASX:PCK) provides a comprehensive business update, revealing significant growth in revenue and expansion of its customer base across multiple regions.</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">PainChek gains access to RTM reimbursement in USA</p><span class="inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400" title="Price sensitive">ðŸš¨ Price Sensitive</span></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>28 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Progress Report</span></div><p class="mt-2 text-xs text-slate-400">PainChek, a leading digital pain management platform from Australian company PACK Healthcare (ASX: PCK), has secured the ability for its users to receive Reimbursements through Real-Time Monitoring systems across various states and territories in the USA. This development is expected</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Quarterly update &amp; Appendix 4C webinar</p></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>27 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Quarterly Report</span></div></div></div></div><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">FAQs</h3><div class="mt-4 space-y-3 text-sm text-slate-300"><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">What does PCK do?</p><p class="text-slate-400">Painchek Ltd develops and commercialises the PainchekÂ® app, an AI-powered medical device for assessing and documenting pain in individuals unable to verbalise it. It&#x27;s primarily used in aged care for people with dementia and is expanding into paediatric and acute care settings globally.</p></div><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">Is PCK a good investment?</p><p class="text-slate-400">As a micro-cap health tech company, PCK is a speculative investment with significant upside potential if its global expansion and adoption succeed, driven by a unique technology addressing an unmet clinical need. However, it carries risks associated with market penetration, capital requirements, and competition common to early-stage growth companies. Investors should be aware of its potential reliance on future capital raises.</p></div><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">What drives PCK&#x27;s share price?</p><p class="text-slate-400">PCK&#x27;s share price is primarily driven by announcements of significant contract wins and partnerships, strong growth in subscriber numbers and recurring revenue, successful international expansion milestones (e.g., regulatory approvals), and any positive clinical validation or government support for its technology. Capital raising activities and broader market sentiment towards speculative health tech stocks also play a role.</p></div></div></div></div><div class="space-y-6"><div class="glass-card rounded-2xl p-6"><h3 class="font-semibold">Key Metrics</h3><div class="mt-4 space-y-4 text-sm"><div class="flex items-center justify-between"><span class="text-slate-400">Share Price</span><span class="font-semibold">A$<!-- -->0.21</span></div><div class="flex items-center justify-between"><span class="text-slate-400">1Y Performance</span><span class="font-semibold text-red-400">-17.6<!-- -->%</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Market Cap</span><span class="font-semibold">A$47M</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Shares on Issue</span><span class="font-semibold">N/A</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Sector</span><span class="font-semibold">Health Care</span></div><div class="flex items-center justify-between"><span class="text-slate-400">IPO Date</span><span class="font-semibold">01/05/2012</span></div></div></div><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">Related Stocks</h3><div class="mt-4 space-y-4"><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CSL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CSL<span class="ml-2 text-sm text-slate-400">CSL Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->180.50</p><p class="text-xs font-semibold text-red-400">-27.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">CSL Ltd is a global biopharmaceutical company specialising in the development, manufacture, and marketing of plasma-derived therapies, vaccines, and recombinant technologies. It holds a dominant market position in critical areas such as immunology, haematology, and influenza prevention through its CSL Behring and Seqirus businesses. The company&#x27;s core operations involve a vast global plasma collection network and advanced manufacturing facilities to produce life-saving treatments.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$87.9B</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PNV/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PNV<span class="ml-2 text-sm text-slate-400">Polynovo Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.92</p><p class="text-xs font-semibold text-red-400">-20.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$687M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/1AD/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">1AD<span class="ml-2 text-sm text-slate-400">Adalta Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.00</p><p class="text-xs font-semibold text-red-400">-40.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$13M</span><span class="text-blue-300">View analysis</span></div></a></div></div></div></section></div></main><footer class="border-t border-white/10 bg-ink-800/60"><div class="mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8"><div><h3 class="font-display text-lg font-semibold">ASX Desk</h3><p class="mt-3 text-sm text-slate-400">Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools.</p><div class="mt-4 flex gap-3"><button class="rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white">Open an Account</button><button class="rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300">Download Media Kit</button></div></div><div class="grid grid-cols-2 gap-6 text-sm text-slate-400"><div><h4 class="mb-2 font-semibold text-slate-200">Platform</h4><ul class="space-y-2"><li><a class="hover:text-white" href="/screener/">Screener</a></li><li><a class="hover:text-white" href="/news/">News &amp; Commentary</a></li><li><a class="hover:text-white" href="/about/">About</a></li></ul></div><div><h4 class="mb-2 font-semibold text-slate-200">Sectors</h4><ul class="space-y-2"><li><a class="hover:text-white" href="/sectors/materials/">Materials</a></li><li><a class="hover:text-white" href="/sectors/financials/">Financials</a></li><li><a class="hover:text-white" href="/sectors/health care/">Health Care</a></li><li><a class="hover:text-white" href="/sectors/information technology/">Information Tech</a></li><li><a class="hover:text-white" href="/sectors/energy/">Energy</a></li></ul></div></div><div class="glass-card rounded-2xl p-6"><h4 class="font-semibold">Weekly Alpha Briefing</h4><p class="mt-2 text-sm text-slate-400">Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox.</p><div class="mt-4 flex flex-col gap-3 sm:flex-row"><input type="email" placeholder="you@example.com" class="w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"/><button class="rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white">Subscribe</button></div><p class="mt-3 text-xs text-slate-500">By subscribing you agree to receive marketing updates. Unsubscribe anytime.</p></div></div><div class="border-t border-white/10 py-6 text-center text-xs text-slate-500"><p>General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results.</p></div></footer></div><script src="/_next/static/chunks/webpack-04cc3a393714a88b.js" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0]);self.__next_f.push([2,null])</script><script>self.__next_f.push([1,"1:HL[\"/_next/static/media/26d4368bf94c0ec4-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n2:HL[\"/_next/static/media/36966cca54120369-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n3:HL[\"/_next/static/css/5bd3404007bffd2a.css\",\"style\"]\n"])</script><script>self.__next_f.push([1,"4:I[5751,[],\"\"]\n7:I[2885,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"669\",\"static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js\"],\"default\"]\n8:I[231,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"669\",\"static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js\"],\"\"]\n9:I[9275,[],\"\"]\nb:I[1343,[],\"\"]\nc:I[8173,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"896\",\"static/chunks/896-78f6f35c40d7ae60.js\",\"391\",\"static/chunks/391-9c591ea098453467.js\",\"185\",\"static/chunks/app/layout-6784eb5ba9ddff8d.js\"],\"Image\"]\nd:I[4019,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"896\",\"static/chunks/896-78f6f35c40d7ae60.js\",\"391\",\"static/chunks/391-9c591ea098453467.js\",\"185\",\"static/chunks/app/layout-6784eb5ba9ddff8d.js\"],\"default\"]\nf:I[6130,[],\"\"]\n6:T5eb,{\"@context\":\"https://schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does PCK do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Painchek Ltd develops and commercialises the PainchekÂ® app, an AI-powered medical device for assessing and documenting pain in individuals unable to verbalise it. It's primarily used in aged care for people with dementia and is expanding into paediatric and acute care settings globally.\"}},{\"@type\":\"Question\",\"name\":\"Is PCK a good investment?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As a micro-cap health tech company, PCK is a speculative investment with significant upside potential if its global expansion and adoption succeed, driven by a unique technology addressing an unmet clinical need. However, it carries risks associated with market penetration, capital requirements, and competition common to early-stage growth companies. Investors should be aware of its potential reliance on future capital raises.\"}},{\"@type\":\"Question\",\"name\":\"What drives PCK's share price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"PCK's share price is primarily driven by announcements of significant contract wins and partnerships, strong growth in subscriber numbers and recurring revenue, successful international expansion milestones "])</script><script>self.__next_f.push([1,"(e.g., regulatory approvals), and any positive clinical validation or government support for its technology. Capital raising activities and broader market sentiment towards speculative health tech stocks also play a role.\"}}]}a:[\"ticker\",\"PCK\",\"d\"]\n10:[]\n"])</script><script>self.__next_f.push([1,"0:[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/5bd3404007bffd2a.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\"}]],[\"$\",\"$L4\",null,{\"buildId\":\"wUJd59QS5gHYngheFxrcw\",\"assetPrefix\":\"\",\"initialCanonicalUrl\":\"/asx/PCK/\",\"initialTree\":[\"\",{\"children\":[\"asx\",{\"children\":[[\"ticker\",\"PCK\",\"d\"],{\"children\":[\"__PAGE__?{\\\"ticker\\\":\\\"PCK\\\"}\",{}]}]}]},\"$undefined\",\"$undefined\",true],\"initialSeedData\":[\"\",{\"children\":[\"asx\",{\"children\":[[\"ticker\",\"PCK\",\"d\"],{\"children\":[\"__PAGE__\",{},[[\"$L5\",[\"$\",\"div\",null,{\"className\":\"space-y-12\",\"children\":[[\"$\",\"script\",null,{\"type\":\"application/ld+json\",\"dangerouslySetInnerHTML\":{\"__html\":\"$6\"}}],[\"$\",\"section\",null,{\"className\":\"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]\",\"children\":[[\"$\",\"div\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.3em] text-blue-300\",\"children\":\"Health Care\"}],[\"$\",\"h1\",null,{\"className\":\"mt-3 font-display text-3xl font-semibold\",\"children\":[\"Painchek Ltd\",\" (\",\"PCK\",\")\"]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-300\",\"children\":\"Painchek Ltd (ASX: PCK) is an Australian health technology company that has developed and commercialised the PainchekÂ® app, an AI-powered pain assessment tool. This medical device uses facial recognition and AI to assess and document pain in individuals who cannot reliably verbalise it, primarily targeting people with dementia in aged care and non-verbal children. The company operates in Australia, the UK, New Zealand, and Canada, aiming to address a significant unmet clinical need globally.\"}],[\"$\",\"div\",null,{\"className\":\"mt-6 grid gap-4 sm:grid-cols-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-500\",\"children\":\"Market Cap\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-lg font-semibold\",\"children\":\"A$47M\"}]]}],[\"$\",\"div\",null,{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-500\",\"children\":\"Shares on Issue\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-lg font-semibold\",\"children\":\"N/A\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"mt-6 flex flex-wrap gap-3 text-xs text-slate-400\",\"children\":[[\"$\",\"a\",null,{\"href\":\"\",\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"Company Website\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"AI coverage updated hourly\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"Data from ASX filings\"}]]}]]}],[\"$\",\"$L7\",null,{\"ticker\":\"PCK\"}],[\"$\",\"section\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"font-display text-xl font-semibold\",\"children\":\"AI Analysis\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4 text-sm text-slate-300\",\"children\":[[\"$\",\"p\",\"Painchek is in a critical growth phase, actively commercialising its PainchekÂ® software-as-a-service (SaaS) platform, particularly within the Australian aged care sector where it has achieved significant penetration. The company generates recurring revenue through subscriptions, with recent performance focused on increasing user adoption, expanding into new aged care facilities, and securing key partnerships. As a micro-cap, its current financial position often reflects ongoing investment in R\u0026D and market expansion, leading to a focus on user growth and revenue trajectory rather than immediate profitability.\",{\"children\":\"Painchek is in a critical growth phase, actively commercialising its PainchekÂ® software-as-a-service (SaaS) platform, particularly within the Australian aged care sector where it has achieved significant penetration. The company generates recurring revenue through subscriptions, with recent performance focused on increasing user adoption, expanding into new aged care facilities, and securing key partnerships. As a micro-cap, its current financial position often reflects ongoing investment in R\u0026D and market expansion, leading to a focus on user growth and revenue trajectory rather than immediate profitability.\"}],[\"$\",\"p\",\"The growth outlook for Painchek is driven by international expansion, especially in large markets like the UK (e.g., NHS uptake) and potential future entry into the US, along with expanding its application into new segments such as paediatrics and acute care. Upcoming catalysts include securing major contracts with national health systems, achieving significant increases in subscriber numbers, and gaining regulatory approvals in new jurisdictions. The strategic direction centres on establishing Painchek as the global standard for pain assessment in non-verbal populations, leveraging its unique AI technology and a strong clinical evidence base.\",{\"children\":\"The growth outlook for Painchek is driven by international expansion, especially in large markets like the UK (e.g., NHS uptake) and potential future entry into the US, along with expanding its application into new segments such as paediatrics and acute care. Upcoming catalysts include securing major contracts with national health systems, achieving significant increases in subscriber numbers, and gaining regulatory approvals in new jurisdictions. The strategic direction centres on establishing Painchek as the global standard for pain assessment in non-verbal populations, leveraging its unique AI technology and a strong clinical evidence base.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"grid gap-6 lg:grid-cols-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"flex items-center gap-2 text-sm font-semibold text-emerald-300\",\"children\":\"Bull Case\"}],[\"$\",\"ul\",null,{\"className\":\"mt-4 space-y-2 text-sm text-slate-300\",\"children\":[[\"$\",\"li\",\"Accelerated international adoption, particularly securing significant contracts with national health systems (e.g., UK NHS, major US aged care groups), leading to a rapid expansion of recurring revenue.\",{\"children\":[\"â€¢ \",\"Accelerated international adoption, particularly securing significant contracts with national health systems (e.g., UK NHS, major US aged care groups), leading to a rapid expansion of recurring revenue.\"]}],[\"$\",\"li\",\"Successful diversification into new clinical segments beyond aged care, such as paediatrics, acute care, and disability support, significantly expanding the addressable market.\",{\"children\":[\"â€¢ \",\"Successful diversification into new clinical segments beyond aged care, such as paediatrics, acute care, and disability support, significantly expanding the addressable market.\"]}],[\"$\",\"li\",\"Strong evidence of improved patient outcomes and cost-effectiveness from Painchek's use, driving increased clinical acceptance, government reimbursement, and mandatory adoption across healthcare settings.\",{\"children\":[\"â€¢ \",\"Strong evidence of improved patient outcomes and cost-effectiveness from Painchek's use, driving increased clinical acceptance, government reimbursement, and mandatory adoption across healthcare settings.\"]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"flex items-center gap-2 text-sm font-semibold text-red-300\",\"children\":\"Bear Case\"}],[\"$\",\"ul\",null,{\"className\":\"mt-4 space-y-2 text-sm text-slate-300\",\"children\":[[\"$\",\"li\",\"Slower than anticipated adoption rates due to market resistance, regulatory hurdles, or challenges in securing large-scale national contracts, impacting revenue growth and cash flow.\",{\"children\":[\"â€¢ \",\"Slower than anticipated adoption rates due to market resistance, regulatory hurdles, or challenges in securing large-scale national contracts, impacting revenue growth and cash flow.\"]}],[\"$\",\"li\",\"Persistent reliance on capital raises to fund ongoing operations and growth initiatives, leading to potential share dilution for existing investors, common for speculative small-cap growth companies.\",{\"children\":[\"â€¢ \",\"Persistent reliance on capital raises to fund ongoing operations and growth initiatives, leading to potential share dilution for existing investors, common for speculative small-cap growth companies.\"]}],[\"$\",\"li\",\"Increased competition from other pain assessment technologies or established clinical practices, or potential technical issues/data security concerns that could undermine trust and market penetration.\",{\"children\":[\"â€¢ \",\"Increased competition from other pain assessment technologies or established clinical practices, or potential technical issues/data security concerns that could undermine trust and market penetration.\"]}]]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Market Sentiment\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center gap-3\",\"children\":[[\"$\",\"span\",null,{\"className\":\"inline-flex items-center gap-1.5 rounded-full border px-3 py-1 text-sm font-semibold bg-yellow-500/10 border-yellow-500/30 text-yellow-400\",\"children\":[\"ðŸŸ¡\",\" \",\"Mixed\"]}],[\"$\",\"span\",null,{\"className\":\"text-xs text-slate-500\",\"children\":[\"Score: \",\"\",\"0.00\"]}]]}],[\"$\",\"div\",null,{\"className\":\"mt-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex justify-between text-[10px] uppercase tracking-widest text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"Bearish\"}],[\"$\",\"span\",null,{\"children\":\"Bullish\"}]]}],[\"$\",\"div\",null,{\"className\":\"relative mt-1 h-2 rounded-full bg-ink-900/60\",\"children\":[[\"$\",\"div\",null,{\"className\":\"absolute left-1/2 top-0 h-full w-px bg-slate-600\"}],[\"$\",\"div\",null,{\"className\":\"absolute top-0 h-full w-2 rounded-full bg-yellow-500\",\"style\":{\"left\":\"calc(50% - 4px)\"}}]]}]]}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex gap-4 text-xs\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-emerald-400\",\"children\":[\"â–² \",0,\" bullish\"]}],[\"$\",\"span\",null,{\"className\":\"text-red-400\",\"children\":[\"â–¼ \",0,\" bearish\"]}],[\"$\",\"span\",null,{\"className\":\"text-slate-500\",\"children\":[10,\" neutral\"]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-1 text-xs text-slate-500\",\"children\":[\"Based on \",10,\" social post\",\"s\"]}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-widest text-slate-500\",\"children\":\"Recent mentions\"}],[[\"$\",\"div\",\"0\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2\",\"children\":[[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400\",\"children\":\"hotcopper\"}],[\"$\",\"span\",null,{\"className\":\"text-slate-500\",\"children\":\"2026-02-07\"}],[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"â€”\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-1.5 text-slate-300\",\"children\":\"Introduction to PainChek Ltd\"}]]}],[\"$\",\"div\",\"1\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2\",\"children\":[[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400\",\"children\":\"hotcopper\"}],[\"$\",\"span\",null,{\"className\":\"text-slate-500\",\"children\":\"2026-02-08\"}],[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"â€”\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-1.5 text-slate-300\",\"children\":\"Informational post about PAINCHEK LTD\"}]]}],[\"$\",\"div\",\"2\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2\",\"children\":[[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400\",\"children\":\"hotcopper\"}],[\"$\",\"span\",null,{\"className\":\"text-slate-500\",\"children\":\"2026-02-08\"}],[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"â€”\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-1.5 text-slate-300\",\"children\":\"Introduction to PainChek Ltd\"}]]}]]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Recent Announcements\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-3 text-sm text-slate-300\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Quarterly Activities/Appendix 4C Cash Flow Report\"}],[\"$\",\"span\",null,{\"className\":\"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400\",\"title\":\"Price sensitive\",\"children\":\"ðŸš¨ Price Sensitive\"}]]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"29 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Quarterly Report\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-xs text-slate-400\",\"children\":\"PCK, a commitments test entity on ASX, has released its quarterly cash flow report detailing significant capital expenditcur and investment activities for the period.\"}]]}],[\"$\",\"div\",\"1\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"PainChek Business Update\"}],[\"$\",\"span\",null,{\"className\":\"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400\",\"title\":\"Price sensitive\",\"children\":\"ðŸš¨ Price Sensitive\"}]]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"29 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Progress Report\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-xs text-slate-400\",\"children\":\"PainChek (ASX:PCK) provides a comprehensive business update, revealing significant growth in revenue and expansion of its customer base across multiple regions.\"}]]}],[\"$\",\"div\",\"2\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"PainChek gains access to RTM reimbursement in USA\"}],[\"$\",\"span\",null,{\"className\":\"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400\",\"title\":\"Price sensitive\",\"children\":\"ðŸš¨ Price Sensitive\"}]]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"28 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Progress Report\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-xs text-slate-400\",\"children\":\"PainChek, a leading digital pain management platform from Australian company PACK Healthcare (ASX: PCK), has secured the ability for its users to receive Reimbursements through Real-Time Monitoring systems across various states and territories in the USA. This development is expected\"}]]}],[\"$\",\"div\",\"3\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Quarterly update \u0026 Appendix 4C webinar\"}],false]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"27 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Quarterly Report\"}]]}],\"\"]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"FAQs\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-3 text-sm text-slate-300\",\"children\":[[\"$\",\"div\",\"What does PCK do?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"What does PCK do?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"Painchek Ltd develops and commercialises the PainchekÂ® app, an AI-powered medical device for assessing and documenting pain in individuals unable to verbalise it. It's primarily used in aged care for people with dementia and is expanding into paediatric and acute care settings globally.\"}]]}],[\"$\",\"div\",\"Is PCK a good investment?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Is PCK a good investment?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"As a micro-cap health tech company, PCK is a speculative investment with significant upside potential if its global expansion and adoption succeed, driven by a unique technology addressing an unmet clinical need. However, it carries risks associated with market penetration, capital requirements, and competition common to early-stage growth companies. Investors should be aware of its potential reliance on future capital raises.\"}]]}],[\"$\",\"div\",\"What drives PCK's share price?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"What drives PCK's share price?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"PCK's share price is primarily driven by announcements of significant contract wins and partnerships, strong growth in subscriber numbers and recurring revenue, successful international expansion milestones (e.g., regulatory approvals), and any positive clinical validation or government support for its technology. Capital raising activities and broader market sentiment towards speculative health tech stocks also play a role.\"}]]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-semibold\",\"children\":\"Key Metrics\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4 text-sm\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Share Price\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":[\"A$\",\"0.21\"]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"1Y Performance\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold text-red-400\",\"children\":[\"-17.6\",\"%\"]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Market Cap\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"A$47M\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Shares on Issue\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"N/A\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Sector\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"Health Care\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"IPO Date\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"01/05/2012\"}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Related Stocks\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4\",\"children\":[[\"$\",\"$L8\",null,{\"href\":\"/asx/CSL\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CSL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"CSL Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"180.50\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-27.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"CSL Ltd is a global biopharmaceutical company specialising in the development, manufacture, and marketing of plasma-derived therapies, vaccines, and recombinant technologies. It holds a dominant market position in critical areas such as immunology, haematology, and influenza prevention through its CSL Behring and Seqirus businesses. The company's core operations involve a vast global plasma collection network and advanced manufacturing facilities to produce life-saving treatments.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$87.9B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L8\",null,{\"href\":\"/asx/PNV\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PNV\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Polynovo Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.92\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-20.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$687M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L8\",null,{\"href\":\"/asx/1AD\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"1AD\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Adalta Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.00\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-40.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$13M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},[\"$\",\"$L9\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"asx\",\"children\",\"$a\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$Lb\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\",\"styles\":null}],null]},[\"$\",\"$L9\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"asx\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$Lb\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\",\"styles\":null}],null]},[[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"__variable_6d343d __variable_49a339\",\"children\":[[\"$\",\"head\",null,{\"children\":[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/logo.svg\",\"type\":\"image/svg+xml\"}]}],[\"$\",\"body\",null,{\"className\":\"min-h-screen bg-ink-900 text-slate-100\",\"children\":[\"$\",\"div\",null,{\"className\":\"min-h-screen\",\"children\":[[\"$\",\"header\",null,{\"className\":\"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8\",\"children\":[[\"$\",\"$L8\",null,{\"href\":\"/\",\"className\":\"flex items-center gap-3\",\"children\":[[\"$\",\"$Lc\",null,{\"src\":\"/logo.svg\",\"alt\":\"ASX Desk\",\"width\":140,\"height\":40,\"className\":\"h-10 w-auto\",\"priority\":true}],[\"$\",\"span\",null,{\"className\":\"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline\",\"children\":\"Research Terminal\"}]]}],[\"$\",\"nav\",null,{\"className\":\"hidden items-center gap-6 text-sm text-slate-300 md:flex\",\"children\":[[\"$\",\"$L8\",\"/\",{\"href\":\"/\",\"className\":\"transition hover:text-white\",\"children\":\"Home\"}],[\"$\",\"$L8\",\"/screener\",{\"href\":\"/screener\",\"className\":\"transition hover:text-white\",\"children\":\"Screener\"}],[\"$\",\"$L8\",\"/sectors\",{\"href\":\"/sectors\",\"className\":\"transition hover:text-white\",\"children\":\"Sectors\"}],[\"$\",\"$L8\",\"/news\",{\"href\":\"/news\",\"className\":\"transition hover:text-white\",\"children\":\"News\"}],[\"$\",\"$L8\",\"/ipos\",{\"href\":\"/ipos\",\"className\":\"transition hover:text-white\",\"children\":\"IPOs\"}],[\"$\",\"$L8\",\"/compare\",{\"href\":\"/compare\",\"className\":\"transition hover:text-white\",\"children\":\"Compare\"}],[\"$\",\"$L8\",\"/about\",{\"href\":\"/about\",\"className\":\"transition hover:text-white\",\"children\":\"About\"}]]}],[\"$\",\"div\",null,{\"className\":\"hidden items-center gap-3 md:flex\",\"children\":[[\"$\",\"$Ld\",null,{}],[\"$\",\"button\",null,{\"className\":\"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20\",\"children\":\"Premium Research\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400\",\"children\":\"Open Account\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex-1\",\"children\":[\"$\",\"$Ld\",null,{}]}],[\"$\",\"$L8\",null,{\"href\":\"/screener\",\"className\":\"shrink-0 text-xs text-blue-300\",\"children\":\"Screener\"}]]}]]}],[\"$\",\"main\",null,{\"className\":\"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8\",\"children\":[\"$\",\"$L9\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$Lb\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[\"$\",\"div\",null,{\"className\":\"flex min-h-[60vh] flex-col items-center justify-center text-center\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.3em] text-blue-300\",\"children\":\"404\"}],[\"$\",\"h1\",null,{\"className\":\"mt-3 font-display text-3xl font-semibold\",\"children\":\"Page not found\"}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-sm text-slate-400\",\"children\":\"We couldn't locate that ASX page. Try searching a ticker or visit the homepage.\"}],[\"$\",\"$L8\",null,{\"href\":\"/\",\"className\":\"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Back to Home\"}]]}],\"notFoundStyles\":[],\"styles\":null}]}],[\"$\",\"footer\",null,{\"className\":\"border-t border-white/10 bg-ink-800/60\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"ASX Desk\"}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-sm text-slate-400\",\"children\":\"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex gap-3\",\"children\":[[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Open an Account\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300\",\"children\":\"Download Media Kit\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"grid grid-cols-2 gap-6 text-sm text-slate-400\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"mb-2 font-semibold text-slate-200\",\"children\":\"Platform\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/screener\",\"className\":\"hover:text-white\",\"children\":\"Screener\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/news\",\"className\":\"hover:text-white\",\"children\":\"News \u0026 Commentary\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/about\",\"className\":\"hover:text-white\",\"children\":\"About\"}]}]]}]]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"mb-2 font-semibold text-slate-200\",\"children\":\"Sectors\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/materials\",\"className\":\"hover:text-white\",\"children\":\"Materials\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/financials\",\"className\":\"hover:text-white\",\"children\":\"Financials\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/health care\",\"className\":\"hover:text-white\",\"children\":\"Health Care\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/information technology\",\"className\":\"hover:text-white\",\"children\":\"Information Tech\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/energy\",\"className\":\"hover:text-white\",\"children\":\"Energy\"}]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h4\",null,{\"className\":\"font-semibold\",\"children\":\"Weekly Alpha Briefing\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-sm text-slate-400\",\"children\":\"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex flex-col gap-3 sm:flex-row\",\"children\":[[\"$\",\"input\",null,{\"type\":\"email\",\"placeholder\":\"you@example.com\",\"className\":\"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Subscribe\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-xs text-slate-500\",\"children\":\"By subscribing you agree to receive marketing updates. Unsubscribe anytime.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"border-t border-white/10 py-6 text-center text-xs text-slate-500\",\"children\":[\"$\",\"p\",null,{\"children\":\"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results.\"}]}]]}]]}]}]]}],null],null],\"couldBeIntercepted\":false,\"initialHead\":[null,\"$Le\"],\"globalErrorComponent\":\"$f\",\"missingSlots\":\"$W10\"}]]\n"])</script><script>self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}],[\"$\",\"meta\",\"1\",{\"charSet\":\"utf-8\"}],[\"$\",\"title\",\"2\",{\"children\":\"PCK share price, analysis \u0026 company profile - Painchek Ltd | ASX Desk\"}],[\"$\",\"meta\",\"3\",{\"name\":\"description\",\"content\":\"Latest PCK share price overview, what Painchek Ltd does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"link\",\"4\",{\"rel\":\"canonical\",\"href\":\"https://asxdesk.com/asx/PCK/\"}],[\"$\",\"meta\",\"5\",{\"property\":\"og:title\",\"content\":\"PCK share price, analysis \u0026 company profile - Painchek Ltd\"}],[\"$\",\"meta\",\"6\",{\"property\":\"og:description\",\"content\":\"Latest PCK share price overview, what Painchek Ltd does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"meta\",\"7\",{\"property\":\"og:url\",\"content\":\"https://asxdesk.com/asx/PCK/\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"9\",{\"name\":\"twitter:card\",\"content\":\"summary_large_image\"}],[\"$\",\"meta\",\"10\",{\"name\":\"twitter:title\",\"content\":\"PCK share price, analysis \u0026 company profile - Painchek Ltd\"}],[\"$\",\"meta\",\"11\",{\"name\":\"twitter:description\",\"content\":\"Latest PCK share price overview, what Painchek Ltd does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"meta\",\"12\",{\"name\":\"next-size-adjust\"}]]\n5:null\n"])</script></body></html>